Regorafenib in Advanced and Refractory Gastrointestinal Cancers - European Medical Journal

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

Download PDF
*Ewen D. Legg

Medical writing assistance was funded by Bayer.

EMJ. ;1[2]:18-25. DOI/10.33590/emj/10313749.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


The American Society of Clinical Oncology’s 2016 Gastrointestinal Cancer Symposium (ASCO-GI), held in San Francisco, California, USA, provided a forum for leading basic scientists and clinical cancer specialists to discuss cutting-edge research in the field of gastrointestinal (GI) oncology. The quest to improve outcomes and patient lives by targeting unmet clinical need, such as refractory illness, fuelled much of the research presented at the 2016 edition of ASCO-GI. The symposium saw the presentation of a number of studies on the current stage of clinical research on regorafenib, an oral tyrosine-kinase inhibitor approved for use in both refractory metastatic colorectal cancer and metastatic GI stromal tumours.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now